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The composition of a Brazilian green propolis ethanolic extract (Et-Bra) and its eﬀect on Trypanosoma cruzi trypomastigotes
and other pathogenic microorganisms have already been reported. Here, we further investigated Et-Bra targets in T. cruzi and its
eﬀect on experimental infection of mice. The IC50/4 days for inhibition of amastigoteproliferation was 8.5 ± 1.8μgmL −1,w i t hn o
damage to the host cells. In epimastigotes Et-Bra induced alterations in reservosomes, Golgi complex and mitochondrion. These
eﬀects were conﬁrmedby ﬂow cytometry analysis.In trypomastigotes, Et-Bra led to the lossof plasmamembrane integrity. The in
vitro studies indicate that Et-Bra interferes in the functionality of the plasma membrane in trypomastigotes and of reservosomes
andmitochondrioninepimastigotes.Acutelyinfected miceweretreated orallywithEt-Braandtheparasitemia,mortalityandGPT,
GOT, CK and urea levels were monitored. The extract (25–300mgkg−1 body weight/day for 10 days) reduced the parasitemia,
although not at signiﬁcant levels; increased the survival of the animals and did not induce any hepatic, muscular lesion or
renal toxicity. Since Et-Bra was not toxic to the animals, it could be assayed in combination with other drugs. Et-Bra could be
a potential metacyclogenesis blocker, considering its eﬀect onreservosomes,which are animportantenergy source during parasite
diﬀerentiation.
1.Introduction
TrypanosomacruziistheetiologicagentofChagasdisease, an
endemicparasitosis inLatin America infecting 16–18million
people [1]. Acute infections are usually asymptomatic, but
the ensuing chronic T. cruzi infections have been associated
with high ratios of morbidity and mortality. At present,
the only accepted drugs for Chagas disease are nifurtimox
(Lampit) and benznidazole (Rochagan or Radanil), eﬀective
for acute infections, but their use for chronic infections is
controversial due to the undesirable side eﬀects, frequently
forcing the abandonment of treatment; the poor indices
of apparent cure and a lack consensus concerning criteria
for parasitological cure. Consequently, the development of
alternative drugs for these nitroderivatives is urgent [2, 3].
Although traditional medicines are used worldwide it
is often diﬃcult to establish how eﬀective they really are.
Only considering parasitic diseases, the examples of quinine
and artemisinin suggest that herbal medicines can be very
eﬀective medically, and underline the fact that natural prod-
ucts are important sources of new pharmaceuticals. In this
context, our laboratory is involved and has been for several
years, in the investigation of the eﬀect of propolison T. cruzi,
using samples with an established chemical composition
[4–6]. Propolis, a product from bees, is extensively used in
folk medicine for a wide spectrum of diseases. This resinous
material is collected from diﬀerent plant exudates and
thus presents a complex composition depending basically
on the plant sources available. Over the last few decades,
an increasing number of studies have been published on
the chemical composition, biological and pharmacological
activities and therapeutic uses of propolis [7]. In temperate
zones, poplar trees (Populus spp.) are the main source of
propolis, while in tropical regions, there are a variety ofplant
sources,leadingtosamples withtotallydistinctcompositions
[8]. Diﬀerent animal models have been used to investigate
propolis as an anti-inﬂammatory [9], cariostatic [10]a n d
anti-parasitic agent [11] and its protective role in models2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Kinetics of the eﬀect of Et-Bra on T. cruzi proliferation.
(a) Epimastigote forms. (b) Amastigotes interiorized in peritoneal
macrophages.
of carcinogenesis [12] and hepatotoxicity [13]. Such eﬀects
have been associated with the presence of ﬂavonoids, aro-
matic acids and esters and their anti-oxidative properties
[14]. Propolis extracts present low toxicity to experimental
animals and humans [15]; in mice the LD50 being higher
than 7gkg−1 [16] and the dose of 1400mgkg−1 body
weight/day for 90 days was proposed as a NOEL (no-eﬀect
level) [17].
Due to its characteristics, Brazilian propolis has been
the subject of intensive research over the last few decades.
It has been sub-divided into four types based on the as-
sociation of ethanol extracts of Brazilian samples with the
levels of bioactive compounds [18]. The subtype BRP1
corresponds to the Brazilian green propolis produced
in Southeastern Brazil and its main botanic source is
Baccharis dracunculifolia (Asteraceae). Green propolis is
highly recommended by modern herbalists since it displays
microbicidal, anti-inﬂammatory, immunomodulatory and
anti-ulcer properties [19]. We previously determined the
chemical composition, the analgesic and anti-inﬂammatory
activities and the in vitro and in vivo eﬀect on T. cruzi of a
standard ethanolextractofaBulgariansample[4,6,20].Our
groupalsocompareditsactivitywith thatofaBraziliangreen
propolis extract (Et-Bra) on T. cruzi and on diﬀerent species
of Leishmania as well as other pathogenic microorganisms
[5, 21]. Giving continuity to the study with Et-Bra, we are
presently investigating potential targets inT. cruzi using elec-
tron microscopy and ﬂow cytometry techniques and also its
eﬀect on the course of experimental acute infection in mice.
2.Materialsand Methods
2.1. Propolis Sample and Preparation of the Extract. The
Brazilian green propolis sample was collected at Mar de
Espanha (State of Minas Gerais, Brazil) from a native forest
with a predominance of B. dracunculifolia. After cooling
below −10◦C the resin was cut in small pieces and extracted
with70%ethanolfor24haspreviouslydescribed[5]andthe
residue was named Et-Bra.
2.2. Parasites. We used the Y strain of T. cruzi.E p i m a s t i g o t e
forms were maintained in LIT medium supplemented with
10% fetal calf serum (FCS) and harvested during the
exponential phase of growth. Bloodstream trypomastigotes
were obtained from infected albino Swiss mice. Amastigotes
were collected from the supernatant of trypomastigote-
infected J-774G-8 macrophage lineage [22].
2.3. Eﬀect on T. cruzi Proliferation. Stock solution of Et-
Bra was prepared in dimethylsulfoxide (Merck, Darmstadt,
Germany). Epimastigotes were resuspended in LIT medium
to a parasite concentration of 10 × 106 cellsmL−1.T h i s
suspension (500μL) was added to an equal volume of the
propolis extract, previously prepared at twice the desired
concentrations in the same medium in 24-well plates
and then incubated at 28◦C. For tissue culture derived-
amastigotes, the protocol was similar: the experiments were
performed at 37◦C in DME plus 10% FCS (DMES) in 96-
well plates (Nunc Inc., Naperville, IL, USA)[23]. Cell counts
were performed after 1 day for amastigotes and up to 4
days for epimastigotes. Et-Bra was assayed in the range of
3–1000μgmL −1 and the ﬁnal concentration of the solvent
never exceeded 0.5%, which had no deleterious eﬀect on the
parasites. The activity of the extracts was expressed as IC50
values, corresponding to the concentration that leads to 50%
inhibition of parasite proliferation.
Peritoneal macrophages were obtained from Swiss mice
andwereplatedin24-wellplates(3×105 cells/well)andafter
24h were infected with trypomastigotes (10:1 parasite:host
cell) in DMES. After interaction for 3h, the cultures were
washed to remove non-interiorized parasites and Et-Bra
was added in a ﬁnal concentration ranging from 15 to
60μgmL −1. At speciﬁed intervals the cultures were ﬁxed in
Bouin’ssolution,stainedwithGiemsaand counted,usingthe
percent ofinfectionand the number ofparasites/infected cellEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: Transmission electron microscopy of T. cruzi epimastigotes treated with Et-Bra for 24h. (a) Control parasite showing the typical
elongated body and normal morphology of mitochondrion (M), Golgi complex (GC), nucleus (N) reservosomes (R), and kinetoplast (k);
(b)50μgmL −1 and(c)100μgmL −1 induced alterationsinthemorphologyofreservosomes(asterisks),withincreaseoftheorganellevolume
andthenumberoflipidinclusionsanddecreaseofproteicmatrixandvacuolization;(d)100μgmL −1 induceddilatationoftheGolgicomplex
cisternae (arrow); (e) 100μgmL −1, (f) 250μgmL −1 and (g, h) 300μgmL −1 caused swelling ofthe mitochondrionwith scarcity ofthe matrix
and mitochondrial cristae (arrowheads), with formationof membrane structures inside the organelle (arrow). Bars: 0.5μm.
as parameters. Host cell viability was measured by the MTT
assay [24].
2.4. Ultrastructural Analysis. Epimastigotes and trypo-
mastigotes (5 × 106 cellsmL−1) were treated for24h with Et-
Bra at concentrations below the corresponding IC50 values.
For trypomastigotes this value was 66.2 ± 3.7μgmL −1 [5].
Treated and controls parasites were processed for ultra-
structural analysis. For scanning electron microscopy, the
parasites were adhered to poly-l-lysine-coated coverslips,
ﬁxedwith2.5%glutaraldehydein0.1MNa-cacodylatebuﬀer
(pH 7.2) at room temperature for 40min and post-ﬁxed
with a solution of 1% OsO4, 0.8% potassium ferricyanide
and 2.5mM CaCl2 i nt h es a m eb u ﬀer for 30min. The cells
were dehydrated in an ascending acetone series, dried by the
critical point method with CO2 (CPD 030, Balzers, Switzer-
land). The samples were mounted with silver cellotape on
aluminum stubs, coated with a 20nm thick gold layer and
examinedina940DSMZeissmicroscope(Oberkochen,Ger-
many). For transmission electron microscopy, after washing
in PBS, the parasites were ﬁxed, post-ﬁxed and dehydrated
as described above and embedded in epoxy resin. Ultrathin
sections(LeicaUltracuts,UCT,Vienna,Austria)werestained
with uranyl acetate and lead citrate and then examined in a
EM10C Zeiss microscope (Oberkochen, Germany).
2.5. Analysis of the Mitochondrion and Acidic Compartments.
After the same treatment described for the ultrastructural
analysis (see above), epimastigotes or trypomastigotes were
incubated for 15min with 10μgmL −1 propidium iodide4 Evidence-Based Complementary and Alternative Medicine
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Figure 3:Scanningelectron microscopyofT. cruzi epimastigotes treated with Et-Bra for 24h:(a) controlparasite withnormalmorphology;
(b) 100μgmL −1, (c) 250μgmL −1 and (d) 400μgmL −1 led to gradual alteration on the morphology, from body shortening to rounded
parasites (arrow) with preservation of the ﬂagellum (arrowheads). Bars: 4μm.
(PI) plus 10μgmL −1 rhodamine 123 (Rh123), or else with
10μgmL −1 acridine orange (AO). Samples were kept on
ice until acquisition using a FACSCalibur ﬂow cytometer
(Becton-Dickinson, CA, USA). The acquisition was per-
formed in FL1 to Rh123, FL2 to AO and FL3 to PI. Analysis
wasperformed using the CellQuestsoftware (JosephTrotter,
Scripps Research Institute, San Diego, CA, USA). Control
and treated parasites were analyzed using a large region (R1)
delimited in FSCXSSC dot plot that could include control
parasites and morphological alterationsinducedby the drug.
Epimastigotes treatedwith Et-Braandlabeledwith AOas
described above were washed in PBS and adhered to poli-l-
lysine-coated glass coverslips and mounted in DABCO. The
material was immediately analyzed and photographed using
epiﬂuorescence microscope (Axioplan, Zeiss).
2.6. In Vivo Studies. Male albino Swiss mice (age 6–8
weeks; weight 18–20g) were maintained in our animal
facilities in stable conditions of temperature and with 12h
light/dark cycles. Mice were separated into the following
groups, each with 8–10 animals: N (non-infected and non-
treated), N-PrX (non-infected and treated with Et-Bra at
Xm g k g −1), Tc (infected and non-treated) and Tc-PrX
(infected and treated with Et-Bra at Xmgkg−1). The doses
of the extract (X) used were 25, 50, 100, 150, 200 or
300mgkg−1. Groups Tc and Tc-PrX were infected with 104
bloodstream trypomastigotes via the intraperitoneal route
(ip). Propolis was administered by gavage for 10 consecutive
days beginning on ﬁrst day post infection (dpi). The body
weight was monitored each week. The level of parasitemia
was checked by the Pizzi-Brener method [25]. Brieﬂy, 5μL
of blood is added between a slide and a coverslip and 50
ﬁelds are counted randomly and the concentration of the
parasites was calculated based on a speciﬁc factor for a given
microscope. The mortality was noted daily and the percent
indices of cumulative mortality (%CM) at 40dpi and the
day when mortality attained 50% (M50)w e r ec a l c u l a t e d .
At diﬀerent points during treatment blood was collected
and immediately submitted to analysis for biochemical
determination of glutamic oxalacetic transaminase (GOT),
glutamate pyruvate transaminase (GPT), urea and total
creatine kinase (CK) using the Reﬂotron System (Roche
Diagnostics, F. Hoﬀmann-La Roche Ltd, Basel, Switzerland).
All procedures were carried out in accordance with the
guidelines established by the FIOCRUZCommittee of Ethics
for the Use of Animals (protocol 0099/01) and by the
Guidelines on the Care and Use of Animals for Experimental
Purposes (NACLAR).
2.7. Statistical Analysis. The comparison between the values
of ﬂuorescence for Rh123, PI and AO was performed
by ANOVA, followed by the Student-Newman-Keuls test.
Statistical signiﬁcance (P < .05) for the in vivo experiments
was evaluated using the Student’s t or ANOVA test for the
parasitemia and the log rank (Mantel-Cox) test for survival
analysis. Kruskall-Wallis and Mann-Whitney tests were used
for comparison of GPT, GOT, urea and CK levels among the
diﬀerent experimental groups.Evidence-Based Complementary and Alternative Medicine 5
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Figure 4: Transmission electron microscopy (a–d) and scanning electron microscopy (e–g) of T. cruzi trypomastigotes treated with Et-Bra
for 24 h: (a) control parasite with the normal morphology of mitochondrion (M), kinetoplast (k) and ﬂagellum (f); (b) 30μgmL −1 and (c,
d) 60μgmL −1 induced the formationof blebs on the body (arrow) and ﬂagellar (arrowheads) membranes. Bars: 0.5μm. (e) control parasite
with the normal morphology; (f, g) 60μgmL −1 leading formation of blebs on the body (arrow) and ﬂagellar (arrowheads) membranes and
some rounded parasites (smallarrow). Bars: 4μm.
3.Results
3.1. In Vivo Eﬀect. Et-Bra caused a dose-dependent inhibi-
tion of T. cruzi proliferation monitored up to 4 days of treat-
ment (Figure 1), intracellular amastigotes (macrophages)
being much more susceptible than epimastigotes (9–19-
fold). In assays with tissue culture-derived amastigotes, the
value of IC50/1 day was 18.7 ± 3.2μgmL −1.T h eI C 50 values
for inhibition of proliferation are displayed in Table 1.T h e
IC50 for the inhibition of macrophage infection was: 28.1 ±
3.7, 16.1 ± 8.3, 13.5 ± 3.1 and 15.1 ± 0.2μgmL −1 for 1, 2,
3a n d4d a y so ft r e a t m e n t ,r e s p e c t i v e l y .D a m a g et ot h eh o s t
cells, determined by the MTT assay, was observed only at
concentrations higher than 60μgmL −1 Et-Bra.
3.2. Ultrastructural Eﬀect. Epimastigotes and trypomastig-
otes were treated for 24h with Et-Bra and analyzed by
transmission (TEM) and scanning electron microscopy
(SEM) (Figures 2, 3 and 4). In epimastigotes, the extract
caused disorganization of the reservosome morphology
(Figures 2(b) and 2(c)), revealed by the reduction of matrix
electron density and the increase of both its volume and
number of lipid droplets, inducing a heterogeneous arrange-
ment of the organelle and the formation of a crystalloid
structure (Figure 2(b)); dilatation of the Golgi complex cis-
ternae (Figure 2(d)); mitochondrial swelling with scarcity of
matrix and cristae and the presence of membrane structures
inside the organelle (Figures 2(e)–2(h)). By SEM, alterations
in epimastigote morphology, shortening and rounding of
the parasite’s body, (Figures 3(b)–3(d)) were observed.
Above400μgmL −1,Et-Brainducedanintensevacuolization,
preventing the identiﬁcation of intracellular organelles and
leadingtothelossofthetypicalmorphologyofepimastigotes
observed by TEM and SEM (data not shown). Treatment6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Flow cytometry analysis of T. cruzi epimastigotes treated with Et-Bra for 24h and incubated with Rh123 and PI or AO. (a–d)
Rh123 ﬂuorescence intensity in: (a) control, (b) 100μgmL −1, (c) 150μgmL −1, (d) 200μgmL −1 Et-Bra. Rh123
high parasites were delimited
by a marker (M1) and the corresponding percent of the cells included. (e) Average ﬂuorescence peak values for the AO ﬂuorescence, from at
least three independent assays, showing a dose-dependent decrease after treatment with Et-Bra. Asterisks indicate P < .05 when compared
to untreated epimastigotes.
Table 1: Values of IC50 (μgmL −1)f o rt h ee ﬀect of Et-Bra on the proliferative forms of T. cruzi.
Days of treatment Epimastigotes Intracellular amastigotes Extracellular amastigotes
1 347.8 ±31.7a 38.5 ±4.6b 18.7 ± 3.2
2 234.5 ± 18.2 16.7 ± 3.0 —
3 218.3 ± 26.4 11.3 ± 2.35 —
4 149.0 ± 4.6 8.5 ± 1.8 —
Dash indicates not determined.
aMean± SD of three independent experiments.
bValues based on the number of parasites/infected macrophage.
of trypomastigotes caused irregular expansions (blebs) of
the body and ﬂagellar membranes (Figures 4(b)–4(d)),
conﬁrmed by SEM analysis (Figures 4(f)–4(g)).
3.3. Flow Cytometry Analysis. Based on the ultrastructural
data,treated parasites were incubatedwith ﬂuorescentmark-
ers for ﬂow cytometry analysis. FSCXSSC dot plots show
that epimastigotes treated with Et-Bra suﬀered dramatic
morphological alterations (data not shown). The extract
induced a decrease in the percentage of Rh123+ cells from
87.7 (control) to 43.5 (300μgmL −1 Et-Bra), indicating a loss
of the mitochondrial membrane potential, although with
membrane integrity, as indicated by PI analysis (Figures
5(b)–5(d)). AO labeling indicated, in comparison with
untreated epimastigotes, a dose-dependent and statistically
signiﬁcant decrease in the average ﬂuorescence peak at
FL2 induced by Et-Bra (Figure 5(e)), a phenomenon also
observed by epiﬂuorescence microscopy (data not shown),
indicating pHincrease in theacidiccompartments. Intrypo-
mastigotes, increasing doses of Et-Bra (15–150μgmL −1)l e d
tomembranedamage,revealedbyadose-dependentincrease
in PI labeling and decreased ﬂuorescence of Rh123high
(Figure 6).
3.4. In Vivo Eﬀect. In relation to in vivo experiments, the
treatment with 25–300mgkg−1 Et-Bra body weight for 10
consecutive days led to statistically signiﬁcant decrease in
the mortality in comparison with control group, while no
important diﬀerences were detected in the parasitemia curve
(Table 2 and Figure 7(a)). In relation to body weight, the
values of infected and treated groups (Tc-PrX) were similar
to those of the group Tc (infected and non-treated), beingEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: Flow cytometry analysis of T. cruzi trypomastigotes treated with Et-Bra for 24 h and incubated with Rh123 and PI. (a–f) Dot
plot of parasites labeled with Rh123 (X axis) and PI (Y axis) and percentages are shown in each quadrant. (a) Control, (b) 15μgmL −1,( c )
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Figure 7: Eﬀect of Et-Bra treatment on T. cruzi-infected in mice: (a) parasitemia and cumulative mortality curves of infected mice (Tc) and
infected andtreated with300μgmL −1 Et-Bra by oralroute, during 10consecutive days.(b) The body weight of the four experimental groups
at days 0, 9 and 17. Asterisks indicate P < .05 for comparison of groups N and Tc.
both signiﬁcantly lower than that of the two non-infected
groups (N and N-PrX) (Figure 7(b)). In all the experimental
groups at day 14 the GPT, GOT, urea and CK levels were
measureddirectlyintheblood.Comparing groupsNand Tc,
it was observed that infection by T. cruzi led to a signiﬁcant
increase in the four markers: 4.0× for GPT, 8.8× for GOT,
1.3× for urea and 3.6× for CK. Administration of Et-Bra
at 300mgkg−1 led to similar levels of GPT, GOT, urea and
CK between the groups N and N-Pr300, indicating that
the treatment of the animals with the extract induced no8 Evidence-Based Complementary and Alternative Medicine
Table 2: Values of the parasitemia peak for the treatment of T. cruzi-infected mice with diﬀerent doses of Et-Bra
a.
Experiment Groups Parasitemia peak (parasites mL−1 (×10−4))
No. 1
Tc 558.2 ± 209.7
Tc-Pr25 399.9 ± 150.0
Tc-Pr50 363.6 ± 151.4
No. 2
Tc 255.6 ± 159.6
Tc-Pr100 205.2 ± 76.9
Tc-Pr150 210.0 ± 80.0
No. 3
Tc 326.0 ± 145.9
Tc-Pr200 255.2 ± 95.6
Tc-Pr300 227.7 ± 33.4
aTreatment for 10 consecutive days beginning at 1dpi.
toxicity, as judged by these parameters, as well as by their
general behavior, also no diﬀerence was observed between
the two infected groups, untreated (Tc) and treated (Tc-
Pr300) (Figure 8 and Table 3).
4.Discussion
Propolis presents a complex composition depending basi-
cally on the plant sources accessible to the bees. Brazil-
ian samples present striking diﬀerences in their chemical
composition when compared with samples from temperate
zones [8]. Besides, diﬀerences are also found among tropical
samples depending on the local ﬂora at the site of collection
[26, 27]. The sample employed in the present work is a green
propolis collected in the State of Minas Gerais, classiﬁed as
aB R P 1[ 18], due to the high content of the bioactive com-
pounds 3,5-diprenyl-4-hydroxycinnamic acid, 2,2-dimethyl-
8-prenyl-2H-1-benzopyran-6-propenoic acid, 3-prenyl-4-
hydroxycinnamic acid, p-coumaric acid and the absence of
2,2-dimethyl-6-carboxyethenyl-2H-1-benzopyran.
TheeﬀectofEt-Brawasinvestigatedonbothproliferative
forms of T. cruzi. Intracellular amastigotes, which are of
clinical relevance, are much more susceptible to the extract
thanepimastigotes. Alterationsinthe host cell were observed
onlyat a concentrationfourtimeshigher than thatneeded to
interfere with parasite proliferation. The eﬀect of the extract
was also much more pronounced on trypomastigotes, the
non-multiplicative form responsible for the transmission of
Chagas disease from the invertebrate to the vertebrate host.
The IC50 for trypomastigotes is 66.2 ± 3.7μgmL −1 while
for benznidazole, the standard drug, this value is 2.8 ±
0.1μgmL −1 [5].
The ultrastructural analysis of epimastigotes treated with
Et-Bra showed morphological alterations in the reservo-
somes, Golgi complex and mitochondrion. Reservosomes
are endocytic compartments found in T. cruzi epimastigotes
and the storage site of endocytosed macromolecules and
lysosomal enzymes. They are bounded by a membrane unit,
with an electron-dense proteic matrix and electron-lucent
lipid inclusions [28]. Similar alterations in reservosomes
and mitochondrion were described for a standard ethanol
extract of a Bulgarian sample, named Et-Blg [6]. Since
reservosomesare crucialforthestorageoflipidsandproteins
in epimastigotes [29], a decrease in their electrondensity
suggests interference of Et-Bra with the accumulation of
ingested macromolecules. Alterations in the Golgi complex
induced by the extract could compromise the glucosylation
and/or protein transport from the endoplasmic reticulum
to secretory vacuoles and lysosomes. Labeling with AO
revealed,byepiﬂuorescence,acidicvesiclesturningtoneutral
ones (yellow to green). Such alteration could be due to
a reduced activity of reservosome H+ p u m pc a u s e db y
membrane damage and the consequent eﬄux of H+ leading
to pH equalization with the cytoplasm. The increase of
lipid accumulation and the lower matrix electrondensity in
reservosomes, together with the decrease of AO ﬂuorescence
and structural alterations of the Golgi suggest that Et-Bra
interferes with the endocytic pathway. The reduction of
the electrondensity by propolis could be due to a lower
content of proteins, essential for the metacyclogenesis to
trypomastigotes [30]. The presence of crystalloid structures
inside reservosomes associated with an increased amount
of lipids were previously described as diﬀerentiated lipid
domains [31]. The increase of the total lipid/protein rate
observed in epimastigotes treated with Et-Bra reinforces the
idea of parasite metabolism alterations leading to its death.
Mitochondrial damage is an alteration usually observed
in parasites incubated with diﬀerent drugs due to the
fundamental role of this organelle on the overall metabolism
of T. cruzi [32]. The ultrastructural damage caused by Et-Bra
on the mitochondrion was conﬁrmed by the ﬂow cytometry
experiments. At concentrations below the IC50 value, Et-
Bra led to a statistically signiﬁcant decrease in the percent
of Rh123high, indicating, interference with the mitochon-
drial membrane hydrogenionic potential. In Et-Bra-treated
trypomastigotes alterations of the plasma membrane were
observed by transmission and scanning electron microscopy,
suggesting that propolis interferes with membrane ﬂuidity
aﬀecting its functionality.
Taken together, these data indicated that, in epimastig-
otes, mitochondria and reservosomes are target organelles
for propolis. In treated trypomastigotes, plasma membrane
damage, interference with the mitochondrion function and
loss of parasite viability were observed. Interestingly no
major mitochondrial damage was detected by TEM; while byEvidence-Based Complementary and Alternative Medicine 9
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Figure 8: Blood levels of the biochemical markers between non-infected (N), non-infected and treated with 300μgmL −1 Et-Bra (N-Pr300),
infected (Tc), and infected and treated with 300μgmL −1 Et-Bra (Tc-Pr300) groups after 14 days. (a) Glutamic oxalacetic transaminase
(GOT), (b) glutamate pyruvate transaminase (GPT), (c) urea, (d) creatine kinase (CK). The values were obtained from three independent
assays.Asterisks indicate P < .05 between groups N and Tc. No statistical diﬀerence was observed when treated with the extract.
Table 3: Blood levels of biochemical markers in the experimental groupsa.
Groups GPT (U/L) GOT (U/L) Urea (mg/dL) CK (U/L)
N 31.0 ± 10.0 99.8 ± 41.1 48.9 ± 14.7 270.6 ± 101.1
N-Pr300 30.6 ± 9.7 84.7 ± 42.0 56.2 ± 13.2 275.1 ± 105.1
Tc 109.9 ±20.9b 573.6 ±289.5b 57.0 ±22.9b 1507.4 ±900.8b
Tc-Pr300 92.6 ± 33.8 647.6 ± 391.1 61.7 ± 22.0 1641.5 ± 675.8
aDeterenation after treatment for 10 consecutive days.
bP<. 05 between groups N and Tc.
ﬂow cytometry a signiﬁcative decrease of Rh123high labeling
was determined, suggesting that a functional alteration
precedes a structural one. How propolis acts has not been
fully clariﬁed, but in the present study we reported for
the ﬁrst time that the treatment of T. cruzi with propolis
interferes with the mitochondrial membrane potential in
both forms of the parasite and with acidic compartments in
epimastigotes.
In continuity, we analyzed the eﬀect of Et-Bra on T.
cruzi-infected mice. The mice infected and not treated with
propolis (Tc) exhibited the classical pattern of parasitemia
and mortality rate as previously described [25]. The extract
induced a non-signiﬁcant decrease of parasitemia levels
when from 25 to 300mgkg−1 Et-Bra was administered from
1 to 10dpi, causing a signiﬁcant decrease of mortality, but
did not reverse the loss of weight induced by the infection.
Treatment with 100mgkg−1 benznidazole induced both a
signiﬁcant decrease of mortality (25%) and of parasitemia
[33]. The activity of the hepatic enzymes, GPT and GOT,
urea and CK was measured in the non-infected (N) and
infected (Tc) groups, to be used as potential markers of T.
cruzi infection. This approach was feasible only up to 14dpi,
since afterwards the number of animals in Tc group grad-
ually decreased, preventing a reliable comparison. Putting10 Evidence-Based Complementary and Alternative Medicine
the results of three independent experiments together, the
valuesof the four parameters for Tc were always signiﬁcantly
higher than those of N. However, it is important to note
the results obtained with urea and CK. For urea, in two
out of three independent experiments no diﬀerence was
observed between groups N and Tc (P = .071 and P = .439),
while in the third one such diﬀerence was signiﬁcative (P =
.016). However, when the values of all the experiments were
taken together, the diﬀerence between these two group was
signiﬁcative (P = .004). For CK, the infected group in each
experiment alwayspresented higher enzyme levelsthan in N.
Therefore, further work is needed to ascertain if urea and CK
are reliable parameters to monitor the course of infection.
The activity of these four biochemical markers was also
evaluated in treated groups to evaluate any potential toxicity
of Et-Bra (N versus N-PrX) and interference in the course
of infection (Tc versus Tc-PrX). Our results show that Et-
Bra up to 300mgkg−1 for 10 days by oral route did not
induce hepatic (GPT, GOT) and renal toxicity (urea) or led
to muscular damage (CK) in non-infected mice. In the Tc-
Pr300 group a signiﬁcant increase in the levels of these four,
atlevelssimilar tothose ofthe infected group,(Tc)occurred,
indicating no protection orexacerbationofthe infection. CK
and the isoenzyme from the heart (CK-MB) increase during
anacuteT. cruzi infectionwith apositivecorrelationbetween
bothenzymes and heart inﬂammatory inﬁltration [34]. Both
enzymes were measured in the plasma using the commercial
kits (Granutest, Merck), after adaptation for low volumes of
plasma [34]. In the present work CK was measured directly
in the blood and a 3.6-fold increase of enzyme levels was
observed in infected mice after 14 days of infection.
Propolis is known as an immunomodulatory agent due
to its known eﬀectson antibody production and on diﬀerent
cellsofthe immune system[35].In thiscontext,experiments
are currently underway in our laboratory to investigate if
Et-Bra exerts any inﬂuence in the immune response in
T. cruzi-infected animals. It would also be interesting to
investigate the association of propolis with benznidazole.
Another aspect that needs to be further analyzed is the
potential role of Et-Bra as a metacyclogenesis blocker, due
to the alterations in the morphology and physiology of
reservosomes here described, since these organelles play a
fundamental role in this diﬀerentiation process in the insect
vector gut.
Funding
This work was supported by CNPq, DECIT/SCTIE/MS,
Papes/FIOCRUZ and FAPERJ.
Acknowledgment
T h ea u t h o r sa r eg r a t e f u lt oD r .L u i sM o r a e sf r o mA p i ´ ario
Amigos da Terra (Nova Friburgo, RJ, Brazil) for the gift of
thesample ofBrazilian propolis,toDr. M.C.Marcucciforits
typiﬁcation, Dr. P. H. Cabello for helpful discussions and to
Marcos Meuser Batista for his excellent technical assistance.
References
[1] WHO, “Control of Chagas disease,” Technical Report Series,
vol. 905, pp. 1–109, 2002.
[2] J. R. Coura and S. L. De Castro, “A critical review on Chagas
disease chemotherapy,” Mem´ orias do Instituto Oswaldo Cruz,
vol. 97, pp. 3–24, 2002.
[3] J. Jannin and L. Villa, “An overview of Chagas disease
treatment,” Mem´ orias do Instituto Oswaldo Cruz, vol. 102, pp.
95–97, 2007.
[ 4 ]E .P r y t z y k ,A .P .D a n t a s ,K .S a l o m ˜ ao et al., “Flavonoids
and trypanocidal activity of Bulgarian propolis,” Journal of
Ethnopharmacology, vol. 88, pp. 189–193, 2003.
[5] K. Salom˜ ao, A. P. Dantas, C. M. Borba et al., “Chemical com-
position and microbicidal activity of extracts from Brazilian
and Bulgarian propolis,” Letters in Applied Microbiology,v o l .
38, pp. 87–92, 2004.
[6] A. P. Dantas, K. Salom˜ ao, H. S. Barbosa, and S. L. De Castro,
“The eﬀect of Bulgarian propolis against Trypanosoma cruzi
and during its interaction with host cells,” Mem´ orias do
Instituto Oswaldo Cruz, vol. 101, pp. 207–211, 2006.
[7] S. L. De Castro, “Propolis: biological and pharmacological
activities. Therapeutic uses of this bee-product,” Annual
Review of Biomedical Sciences, vol. 3, pp. 49–83, 2001.
[8] M. C. Marcucci and V. S. Bankova, “Chemical composition,
plant origin and biological activity of Brazilian propolis,”
Current Topics in Phytochemistry, vol. 2, pp. 115–123, 1999.
[ 9 ]L .B .S y ,Y .L .W u ,B .L .C h i a n g ,Y .H .W a n g ,a n dW .M .
Wu, “Propolis extracts exhibit an immunoregulatory activity
in an OVA-sensitized airway inﬂammatory animal model,”
International Immunopharmacology, vol. 6, pp. 1053–1060,
2006.
[10] A. Sabir, C. R. Tabbu, P. Agustiono, and W. Sosroseno,
“Histological analysis of rat dental pulp tissue capped with
propolis,” J o u r n a lo fO r a lS c i e n c e , vol. 47, pp. 135–138, 2005.
[11] J. Starzyk, S. Scheller, J. Szaﬂarski, M. Moskwa, and A. Stojko,
“Biological properties and clinical application of propolis.
II. Studies on the antiprotozoan activity of ethanol extract
of propolis,” Arzneimittel-Forschung, vol. 27, pp. 1198–1199,
1977.
[12] R. Padmavathi, P. Senthilnathan, D. Chodon, and D. Sak-
thisekaran, “Therapeutic eﬀect of paclitaxel and propolis on
lipid peroxidation and antioxidant system in 7,12-dimethyl
benz(a)anthracene-induced breast cancer in female Sprague
Dawley rats,” Life Science, vol. 78, pp. 2820–2825, 2006.
[ 1 3 ]A .S .E l - K h a t i b ,A .M .A g h a ,L .G .M a h r a n ,a n dM .T .
Khayyal, “Prophylactic eﬀect of aqueous propolis extract
against acute experimental hepatotoxicity in vivo,” Zeitschrift
f¨ ur Naturforschung, vol. 57C, pp. 379–385, 2002.
[14] H. Ichikawa, K. Satoh, T. Tobe et al., “Free radical scavenging
activity of propolis,” Redox Report, vol. 7, pp. 347–350, 2002.
[15] I. Jasprica, A. Mornar, Z. Debeljak et al., “In vivo study of
propolis supplementation eﬀects on antioxidative status and
red blood cells,” Journal of Ethnopharmacology, vol. 110, pp.
548–554, 2007.
[16] A. Arvouet-Grand, B. Lejeune, P. Bastide, A. Pourrat, A. M.
Privat, and P. Legret, “Propolis extract. I. Acute toxicity and
determination of acute primary cutaneous irritation index,”
Journal de Pharmacie de Belgique, vol. 48, pp. 165–170, 1993.
[17] I. Hollands, A. Vidal, and M. Sotolongo, “Evaluation of
the sub-chronic toxicity of Cuban propolis,” Revista Cubana
Ciencias Veterinarias, vol. 1, pp. 157–163, 1991.Evidence-Based Complementary and Alternative Medicine 11
[18] M. C. Marcucci, “Process to typing natural products,”
Requested patent. Brazilian National Institute for Intellectual
Property (INPI), n◦, PI 0105471-6, December 2000.
[19] N. Paulino, C. Teixeira, R. Martins et al., “Evaluation of the
analgesic and anti-inﬂammatory eﬀects of Brazilian green
propolis,” Planta Medica, vol. 72, pp. 899–906, 2006.
[20] N. Paulino, A. P. Dantas, V. S. Bankova et al., “Bulgarian
propolis induces analgesic and anti-inﬂammatory eﬀects in
mice and inhibits in vitro contraction of airway smooth
muscle,” Journal of Pharmacological Sciences, vol. 93, pp. 307–
313, 2003.
[21] G. M. C. Machado, L. L. Leon, and S. L. De Castro, “Activity
of Brazilianand Bulgarian propolis against diﬀerent species of
Leishmania,” Mem´ oriasdoInstitutoOswaldo Cruz,vol.102,pp.
73–77, 2007.
[ 2 2 ]S .L .D eC a s t r o ,M .N .L .M e i r e l l e s ,a n dM .M .O l i v e i r a ,
“Trypanosoma cruzi: adrenergic modulation of cAMP role
in proliferation and diﬀerentiation of amastigotes in vitro,”
Experimental Parasitology, vol. 64, pp. 368–375, 1987.
[23] R. M. Santa-Rita, R. Lira, H. S. Barbosa, J. A. Urbina, and S.
L.De Castro,“Antiproliferative synergismoflysophospholipid
analogues and ketoconazoleagainst Trypanosoma cruzi (Kine-
toplastida: Trypanosomatidae): cellular and ultrastructural
analysis,” Journal of Antimicrobial Chemotherapy,v o l .5 5 ,p p .
780–784, 2005.
[24] T. Mosmann, “Rapid colorimetric assay for cellular growth
and survival: application to proliferation and cytotoxicity
assays,” Journal of Immunological Methods, vol. 65, pp. 55–63,
1983.
[25] Z. Brener, “Therapeutic activity and criterion of cure on mice
experimentally infected with Trypanosoma cruzi,” Revista do
InstitutodeMedicinaTropicaldeS˜ aoPaulo,vol.4,pp.386–396,
1962.
[ 2 6 ]Y .K .P a r k ,S .M .A l e n c a r ,a n dC .L .A g u i a r ,“ B o t a n i c a lo r i g i n
and chemical composition of Brazilian propolis,” Journal of
Agricultural and Food Chemistry,vol.50,pp. 2502–2506,2002.
[27] M. C. Marcucci, F. Ferreres, C. Garcia-Viguera et al., “Phenolic
compounds from Brazilian propolis with pharmacological
activities,” Journal of Ethnopharmacology, vol.74,pp. 105–112,
2001.
[28] C. Sant’Anna, M. G. Pereira, L. Lemgruber, W. de Souza,
and N. L. Cunha-e-Silva, “New insights into the morphology
of Trypanosoma cruzi reservosome,” Microscopy Research and
Technique, vol. 71, pp. 599–605, 2008.
[29] M. J. Soares, “Endocytic portals in Trypanosoma cruzi epi-
mastigote forms,” Parasitology Research, vol. 99, pp. 321–322,
2006.
[ 3 0 ] R .C .F i g u e i r e d o ,D .S .R o s a ,a n dM .J .S o a r e s ,“ D i ﬀerentiation
of Trypanosoma cruzi epimastigotes: metacyclogenesis and
adhesion to substrate are triggered by nutritional stress,”
Journal of Parasitology, vol. 86, pp. 1213–1218, 2000.
[31] N. Cunha-e-Silva, C. Sant’Anna, M. G. Pereira, I. Porto-
Carreiro, A. L. Jeovanio, and W. De Souza, “Reservosomes:
multipurpose organelles?” Parasitology Research, vol. 99, pp.
325–327, 2006.
[ 3 2 ]R .F .S .M e n n a - B a r r e t o ,K .S a l o m ˜ a o ,A .P .D a n t a se ta l . ,“ D i f -
ferent cell death pathways induced by drugs in Trypanosoma
cruzi: an ultrastructural study,” Micron, vol. 40, pp. 157–168,
2009.
[33] D. A. Oliveira, D. G. Pereira, A. M. A. P. Fernandes et al.,
“Trypanocidal activity of 2-propen-1-amine derivatives on
trypomastigotes culture and in animal model,” Parasitology
Research, vol. 95, pp. 161–166, 2005.
[34] A. P. Souza, B. P. Olivieri, S. L. De Castro, and T. C. Ara´ ujo-
Jorge, “Enzymatic markers of heart lesion in mice infected
with Trypanosoma cruzi and submitted to benznidazole
chemotherapy,” Parasitology Research, vol. 86, pp. 800–808,
2000.
[35] J. M. Sforcin, “Propolis and the immune systemml: a review,”
Journal of Ethnopharmacology, vol. 113, pp. 1–4, 2007.